Age dependent prognosis in concurrent chemo-radiation of locally advanced NSCLC

Acta Oncologica

Volumn 54, Issue 3, 2015, Pages 333-339

  Hansen, Olfred ^a,b   Schytte, Tine ^a,b   Nielsen, Morten ^a   Brink, Carsten ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; ETOPOSIDE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RADIATION DOSE; UNIVERSITY HOSPITAL; AGE FACTORS; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RADIOTHERAPY DOSAGE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY DOSAGE;

EID: 84924274526     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.958529     Document Type: Article

References (25)

1. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-90.
2. O'Rourke N, Roque IF, Farre BN, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010;CD002140.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lunge cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
4. Aridgides PD, Janik A, Bogart JA, Duffy S, Rosenbaum P, Gajra A. Radiotherapy for stage I non-small-cell lung carcinoma in the elderly (age >/ = 70 years). Clin Lung Cancer 2013;14:674-9.
5. Jalal IS, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M, et al. Updated survival and outcomes for older adults with inoperable stage I non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: Analysis of a phase I trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol 2012;23:1730-8.
6. Lee JH, Wu HG, Kim HJ, Kim DW, Lee SH, Kim TM, et al. Influence of comorbidities on the efficacy of radiotherapy with or without chemotherapy in elderly stage III non-small cell lung cancer patients. Cancer Res Treat 2012;44:242-50.
7. Coate LE, Massey C, Hope A, Sacher A, Barrett K, Pierre A, et al. Treatment of the elderly when cure is the goal: The influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J Thorac Oncol 2011;6:537-44.
8. Schytte T, Nielsen TB, Brink C, Hansen O. Pattern of local failure in non-small cell lung cancer patients treated with definitive radiotherapy. Acta Oncol 2014;53:336-41.
9. Jeppesen S, Schytte T, Jensen HR, Brink C, Hansen O. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: An updated retrospective study on local failure and survival rates. Acta Oncol 2013;52:1552-8.
10. Schytte T, Hansen O, Stolberg-Rohr T, Brink C. Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer. Acta Oncol 2010;49:1058-60.
11. Nielsen M, Hansen O, Vach W. Attempts to predict the longterm decrease in lung function due to radiotherapy of nonsmall cell lung cancer. Radiother Oncol 2006;78:165-8.
12. th ed (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
13. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the tnm stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:706-14.
14. Rocha Lima CM, Herndon I JE, Kosty M, Clamon G, Green MR. Therapy choices among older patients with lung carcinoma: An evaluation of two trials of the cancer and leukemia group B. Cancer 2002;94:181-7.
15. Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76:S70-6.
16. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013;85:444-50.
17. Wanders R, Steevens J, Botterweck A, Dingemans AM, Reymen B, Baardwijk A, et al. Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: A prospective population-based study. Eur J Cancer 2011;47:2691-7.
18. rd ed. American College of Chest Physicians evidence- based clinical practice guidelines. Chest 2013;143: e314S-40S.
19. Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: A randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012;13:671-8.
20. Langer CJ, Hsu C, Curran WJ, Komaki R, Lee JS, Byhardt RB, et al. Elderly patients (pts) with locally advanced nonsmall cell lung cancer (LA-NSCLC) benefit from combined modality therapy: Secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Ann Meet Am Soc Clin Oncol 2002;21:299a(Abstract 1193).
21. Schild SE, Mandrekar SJ, Jatoi A, McGinnis WL, Stella PJ, Deming RL, et al. The value of combined-modality therapy in elderly patients with stage I nonsmall cell lung cancer. Cancer 2007;110:363-8.
22. Holgersson G, Hoye E, Bergqvist M, Ekman S, Nyman J, Helsing M, et al. Swedish Lung Cancer Radiation Study Group: Predictive value of age at diagnosis for radiotherapy response in patients with non-small cell lung cancer. Acta Oncol 2012;51:759-67.
23. Leprieur EG, Fernandez D, Chatellier G, Klotz S, Giraud P, Durdux C. Acute radiation pneumonitis after conformational radiotherapy for nonsmall cell lung cancer: Clinical, dosimetric, and associated-treatment risk factors. J Cancer Res Ther 2013;9:447-51.
24. Salama JK, Stinchcombe TE, Gu L, Wang X, Morano K, Bogart JA, et al. Pulmonary toxicity in stage I non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: A secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Int J Radiat Oncol Biol Phys 2011;81:e269-74.
25. Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, Araki T, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage I non-small cell lung cancer: A good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003;40: 79-84.